Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK‐fusion‐positive lung cancer

Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK‐fusion‐positive lung cancer

Cancers can develop resistance to treatment with ALK tyrosine kinase inhibitors (ALK‐TKIs) via emergence of a subpopulation of drug‐tolerant persister (DTP) cells that can survive initial drug treatment long enough to acquire genetic aberrations. DTP cells are thus a potential therapeutic target. We...

Full description

Saved in:
Bibliographic Details
Main Authors: Koh Furugaki, Takaaki Fujimura, Narumi Sakaguchi, Yasutaka Watanabe, Ken Uchibori, Eisaku Miyauchi, Hidetoshi Hayashi, Ryohei Katayama, Shigeki Yoshiura
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:Molecular Oncology
Subjects:
ALK
drug‐tolerant persister
EGFR
FGFR
GPX4
Online Access:https://doi.org/10.1002/1878-0261.13746
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items